発表論文一覧
| No | 試験名 | 雑誌 | 論文名 | 執筆者 |
| 2025年度(2025年4月～2026年3月)発表論文 | ||||
| 1 | LOGIK2002 |
Lung Cancer 203 (2025) 108543
|
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002) |
九州大学 白石 祥理 |
| 2 | LOGIK2003 |
JTO Clinical and Research Reports
|
Turtle study: A phase II study of durvalumab plus carboplatin and etoposide in elderly patients with extensive-stage small-cell lung cancer (LOGiK 2003) |
久留米大学 石井 秀宣 |
| 3 | J-FOCAL |
Journal of Obstetrics and Gynaecology Research 2025; 51, e16325 |
Multicenter cohort study of the effect of Crinone® progesterone vaginal gel alone to prepare the endometrium for frozen–thawed blastocyst transfer in a hormone replacement cycle |
東邦大学 医療センター 佐倉病院 高島 明子 |
| 4 |
LOGIK0902/ OLCSG0905 |
Cureus 17(6): e86575.
|
Retreatment With EGFR-Tyrosine Kinase Inhibitor After Disease Progression Following Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant Stage III Non-small Lung Cancer: An Efficacy and Safety Analysis of the LOGIK0902/OLCSG0905 Study |
熊本中央病院 佐伯 祥 |
| 5 | LOGIK2001 |
ESMO Open 2025; 10: 105325.
|
Platinum plus etoposide with durvalumab for extensive-stage small-cell lung cancer with untreated brain metastases: a multicenter, single-arm phase II trial (LOGiK2001, SPEED) |
九州大学 白石 祥理 |
| 6 |
肺の生活習慣病 コホート研究 |
Respirology
|
Association between single nucleotide polymorphisms and disease susceptibility, survival, and acute exacerbation in idiopathic pulmonary fibrosis |
九州大学 坪内 和哉 |
| 7 | W-JHS AA01 |
British Journal of Haematology
|
Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study |
国立 国際医療センター 石山 謙 |
| 8 |
肺の生活習慣病 コホート研究 |
BMC Pulmonary Medicine
|
Prognostic impact of muscle mass in idiopathic interstitial pneumonia: analysis of idiopathic pulmonary fibrosis and other idiopathic interstitial pneumonias |
九州大学 萩原 拓貴 |
| 9 | LOGIK2102 |
European Journal of Cancer
|
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non–small cell lung cancer: a multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102) |
九州大学 白石 祥理 |
| 10 | TOP-ILD |
ERJ Open Research
|
Upfront combination therapy with nintedanib and anti-inflammatory agents for progressive pulmonary fibrosis: a multicenter, single-arm phase 2 study (TOP-ILD) |
九州大学 坪内 和哉 |
| 11 | LOGIK2401 |
Cancer Treatment and Research Communications
|
Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study) |
久留米大学 石井 秀宣 |
| 12 | LCI-detection study |
Scientific Reports 2025; 15:36788 |
Linked color imaging improves polyp miss rates in total colonoscopy in a multicenter randomized back to back trial |
佐賀大学 下田 良 |
| 13 |
肺の生活習慣病 コホート研究 |
Scientific Reports 2025; 15(1):38705. |
Diagnostic utility of high-mobility group box 1 for acute exacerbations of idiopathic pulmonary fibrosis |
福岡大学 濱田 直樹 |
| 14 | POLASTAR |
International Journal of Hematology
|
Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR) |
関西医科大学 佐竹 敦志 |
| 15 | KYUCOG-1901 |
Cancer Science
|
Effectiveness and Safety of Radium-223 for Bone-Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study |
九州大学 塩田 真己 |
| 16 | W-JHS AA02 |
British Journal of Haematology
|
Phase II study of the triple combination of rabbit ATG, cyclosporine, and eltrombopag in patients with transfusion-dependent aplastic anemia: West Japan Hematology Study Group (W-JHS) AA02 trial |
獨協医科大学 中村 文美 |
| 17 | TEMPER study |
International Journal of Clinical Oncology
|
Modified EXTREME regimen versus modified TPEx regimen as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, open-label, randomized, exploratory study (TEMPER study) |
大阪大学 鈴木 基之 |
| 18 | KYUCOG-1901 |
European Journal of Nuclear Medicine and Molecular Imaging
|
Impact of radium-223 on bone imaging and biochemical markers with and without bone-modifying agents in bone-metastatic castration-resistant prostate cancer: results from the kyucog-1901 study |
九州大学 塩田 真己 |
| 2024年度(2024年4月～2025年3月)発表論文 | ||||
| 1 | SNiP-RCC | Journal of Immunology 2024 May 17:ji2300308. |
Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study | 九州大学 種子島 時祥 |
| 2 | Cryo-tsc | JU Open Plus 2(6):e00051, June 2024. |
Safety and Efficacy of Cryotherapy for the Treatment of Renal Angiomyolipoma Related to Tuberous Sclerosis Complex: The Cryo-TSC Study | 九州大学 柏木 英史 |
| 3 | LOGIK1902 | Thoracic Cancer |
A phase II study of weekly carboplatin and concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer (LOGIK1902) | JCHO九州病院 原田 大志 |
| 4 | LOGIK2004 | European Journal of Cancer |
Nivolumab plus Ipilimumab with Chemotherapy for Non–Small Cell Lung Cancer with Untreated Brain Metastases: A Nonrandomized Controlled Phase 2 Trial(NIke, LOGiK 2004) | 北九州市立 医療センター 土屋 裕子 |
| 5 | 肺の生活習慣病 コホート研究 |
BMC Pulmonary Medicine |
Update of prognosis and characteristics of chronic obstructive pulmonary disease in a real-world setting: a 5-year follow-up analysis of a multi-institutional registry | 九州大学 髙野 智嗣 |
| 6 | BIONEXT | Frontiers in Immunology |
Nationwide multi-centric prospective study for the identification of biomarkers to predict the treatment responses of nivolumab through comprehensive analyses of pretreatment plasma exosome mRNAs from head and neck cancer patients (BIONEXT study) | 九州がんセンター 佐藤 晋彰 |
| 7 | LOGIK0902/ OLCSG0905 |
International Journal of Clinical Oncology |
Five-Year Outcomes with Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant Stage III Non-Small-Cell Lung Cancer: LOGIK0902/OLCSG0905 Phase II Study | 岡山大学 堀田 勝幸 |
| 2023年度(2023年4月～2024年3月)発表論文 | ||||
| 1 | RAMNITA | The Oncologist 2023 Jun; 28(6): 551–e454 |
Ramucirumab plus docetaxel for non–small cell lung cancer patients with brain metastases: A multicenter, open-label single-arm phase II trial | 京都府立医科大学 谷村 恵子 |
| 2 | TCOG_LC1901 (UNICORN) |
Journal of Clinical Oncology 2023; 41: 9045-9045. |
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study. Meeting Abstract 2023 ASCO Annual Meeting I |
国立がんセンター 中央病院 大熊 裕介 |
| 3 | SPIRAL-DACO | Cancer Medicine |
Prophylactic treatment of dacomitinib-induced skin toxicities in EGFR-mutated non–small-cell lung cancer: a multicenter, phase II trial | 京都府立医科大学 岩破 將博 |
| 4 | SPIRAL-3D | Therapeutic Advances in Medical Oncology 2023;15:1-8 |
Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study) | 京都府立医科大学 河内 勇人 |
| 5 | KYUCOG-1401A | Endocr Relat Cancer 2023 Jun 1;30(7):e230044. |
Genome-wide association studies identified genetic polymorphisms associated with prognosis in patients undergoing primary androgen deprivation therapy for advanced prostate cancer: KYUCOG-1401-A study | 九州大学 塩田 真己 |
| 6 | SNiP-RCC | International Journal of Urology 2023 Sep;30(9):788-796. |
Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study | 九州大学 Leandro Blas |
| 7 | SPIRAL-BRAIN | Translational Lung Cancer Research 2023 Aug 30;12(8):1802-1806. |
A protocol of a single arm, prospective, open-label, multicenter, phase II study of ramucirumab and erlotinib in treatment-naïve non-small cell lung cancer patients with EGFR mutation and brain metastases (SPIRAL-BRAIN study) |
京都府立医科大学 澤田 凌 |
| 8 | TORG1938 (EPONA) |
Future Oncology 2023 Jul;19(22):1515-1521. |
Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study) | 国立がんセンター 中央病院 大熊 裕介 |
| 9 | BIO-NEXT | Preprint server medRxiv |
Prospective exploration of a prognostic biomarker of nivolumab for head and neck cancer patients (BIONEXT) | 九州がんセンター 佐藤 晋彰 |
| 10 | LOGIK1603 | JTO Clinical and Research Reports |
A Phase II Single-Arm Study of Osimertinib for Radiotherapy-Naive CNS Metastasis Non-Small Cell Lung Cancer: Results for the First-line cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L) | 静岡県立 静岡がんセンター 和久田 一茂 |
| 11 | SPIRAL-RT | European Journal of Cancer |
A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: the SPIRAL-RT study | 京都府立医科大学 山田 忠明 |
| 12 | 肺の生活習慣病 コホート研究 |
BMJ Open Respiratory Research |
Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry | 九州大学 坪内 和哉 |
| 13 | TCOG_LC1901 (UNICORN) |
JAMA Oncology 2024 Jan 1;10(1):43-51. |
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial | 国立がんセンター 中央病院 大熊 裕介 |
| 14 | KYUCOG-1401 | International Journal of Urology |
GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401 | 原三信病院 横溝 晃 |
| 15 | LOGIK2301 | Clinical Lung Cancer |
Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with Completely Resected Stage II/III Non-Small Cell Lung Cancer: RELIANCE trial | 北九州医療センター 松原 太一 |
| 16 | SPADE | European Journal of Obstetrics & Gynecology and Reproductive Biology |
The effects of dienogest and combined oral contraceptives on protein S-specific activity in endometriosis patients | 九州大学 横田 奈津子 |
| 17 | KYUCOG-1401A | Prostate Cancer & Prostatic Disease |
The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: The KYUCOG-1401-A study | 九州大学 塩田 真己 |
| 18 | W-JHS NHL01 | International Journal of Hematology |
End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan Hematology Study Group (W-JHS) NHL01 trial |
九州大学 加藤 光次 |
| 2022年度(2022年4月～2023年3月)発表論文 | ||||
| 1 | LOGIK1303 | JMA Journal 2022; 5: 334–40. |
Efficacy and Safety of Sitafloxacin in Treating Low-risk Febrile Neutropenia in Patients with Lung Cancer | 福岡大学 温 麟太郎 |
| 2 | 福岡和白病院・浅間総合病院 共同研究 |
Current Medical Research and Opinion 2022 Sep;38(9):1567-1578 |
Effects of pericapsular soft tissue and realignment exercises for patients with osteoarthritis of the hip and Harris Hip Score below 60 points | 和白病院 林 和生 |
| 3 | W-JHS MDS01 | International Journal of Hematology |
ASXL1 mutations with serum EPO levels predict a poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial | 近畿大学 森田 泰慶 |
| 4 | LOGIK1605 | Thoracic Cancer 2022;13:2499–506 |
Phase II study of S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Results of the LOGIK1605/JART-1501 study | 長崎県島原病院 福田 実 |
| 5 | LOGIK2002 | BMC Cancer (2022) 22:964 |
Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial | 九州大学 白石 祥理 |
| 6 | SPIRAL-0 | The Oncologist |
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study | 宇治徳洲会病院 千原 佑介 |
| 7 | SPIRAL-II | JTO Clinical and Research Reports |
Osimertinib and bevacizumab co-treatment for untreated epidermal growth factor receptor–mutated non-small-cell lung cancer with malignant pleural and/or pericardial effusion (SPIRAL II): A single-arm, open-label, phase II clinical trial | 湘南藤沢徳洲会病院 日比野 真 |
| 8 | LOGIK2003 | Thoracic Cancer 2022;1–3 |
Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003) | 久留米大学 石井 秀宣 |
| 9 | LOGIK2001 | Cancer Management and Research 2022:14 3449–3453 |
Forthcoming Phase II Study of Durvalumab (MEDI4736) plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases | 九州大学 白石 祥理 |
| 10 | B-PAD | Clin Exp Allergy 2023 Feb;53(2):233-238. |
Exploring biomarkers to predict clinical improvement of Atopic Dermatitis in patients treated with dupilumab (B-PAD study) | 九州大学 中原 剛士 |
| 11 | SNiP-RCC | Cancer Immunology, Immunotherapy |
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial | 九州大学 塩田 真己 |
| 2021年度(2021年4月～2022年3月)発表論文 | ||||
| 1 | LOGIK1607 | JTO Clinical and Research Reports |
High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib | 大分大学 小副川 敦 |
| 2 | LOGIK0902 | ESMO Open 2021 Aug;6(4):100191 |
Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study | 岡山大学 堀田 勝幸 |
| 3 | LOGIK1603 | Journal of Thoracic Oncology | A phase II study of osimertinib for radiotherapy-naïve CNS metastasis from non-small cell lung cancer: Results for the T790M cohort of the OCEAN study (LOGIK1603/WJOG9116L) | 長崎大学 山口 博之 |
| 4 | LOGIK2004 | Cancer Management and Research 2021;13:8489-93 |
Phase II Study of Nivolumab plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naïve Advanced Non–Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004) | 北九州医療センター 土屋（河野） 裕子 |
| 5 | TCOG_LC1901 (UNICORN) |
Future Oncology VOL. 18, NO. 5 |
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901) | 国立がんセンター 中央病院 大熊 裕介 |
| 6 | LOGIK1601 | International Journal of Clinical Oncology | A prospective observational study of postoperative adjuvant chemotherapy for non‑small cell lung cancer in elderly patients (≥ 75 years) | 別府医療センター 矢野 篤次郎 |
| 2020年度(2020年4月～2021年3月)発表論文 | ||||
| 1 | LOGIK1101 | The Oncologist 2020;25:1-10 |
Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study | 九州がんセンター 野崎 要 |
| 2 | LOGIK0602 | BMC Cancer 2020 4;20(1):1192 |
A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study | 長崎大学 土屋 智史 |
| 3 | LOGIK 1603 /WJOG 9116L | BMC Cancer (プロトコール論文) 2020 1;20(1):370 |
A Phase II Study of Osimertinib for Patients with Radiotherapy-naive CNS Metastasis of Non-Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the OCEAN Study | 長崎大学 福田 実 |
| 4 | LOGIK1604 | Eur J Cancer . 2021;149:14-22 |
Osimertinib Versus Osimertinib Plus Chemotherapy for Non-Small Cell Lung Cancer with EGFR (T790M)-Associated Resistance to Initial EGFR Inhibitor Treatment: An Open-Label, Randomized Phase 2 Clinical Trial | 九州大学 田中 謙太郎 |
| 5 | SPIRAL-Study | J. Clin. Med. 2020 5;9(6):1762 |
Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment | 福岡大学 中尾 明 |
| 6 | FRABR_ABT02 | Immunological Medicine 2020 29;1-5. |
Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production | 九州大学 山田 久方 |
| 7 | CONTACT | Neurourology and Urodynamics 2020; 39: 804-12. |
A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study) | 獨協医科大学病院 山西 友則 |
| 8 | GAP | Lower Urinary Tract Symptoms. 2021; 13(2):224-229. |
Prevalence of xerostomia with or without overactive bladder symptoms | 新潟大学 伊藤 加代子 |
| 9 | QUATRO Study | BMC Ophthalmology 2021 21:58 |
Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study | 九州大学 大島 裕司 |
| 10 | DIrecT Study | Urologia Internationalis 2021 9;1-9 |
Triple therapy with tamsulosin, dutasteride, and imidafenacin for benign prostatic hyperplasia in patients with overactive bladder symptoms refractory to tamsulosin: Subgroup analyses of DIrecT study | 獨協医科大学病院 山西 友則 |
| 11 | 洗浄剤 | Advances in Wound Care 2021 Mar 30. |
Effects of hand hygiene using 4% chlorhexidine gluconate or natural soap during hand rubbing followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion in the operating room | 福岡大学 秋田 定伯 |